[go: up one dir, main page]

BRPI0508813A - vacinas de combinação com baixa dose de conjugado de hib - Google Patents

vacinas de combinação com baixa dose de conjugado de hib

Info

Publication number
BRPI0508813A
BRPI0508813A BRPI0508813-5A BRPI0508813A BRPI0508813A BR PI0508813 A BRPI0508813 A BR PI0508813A BR PI0508813 A BRPI0508813 A BR PI0508813A BR PI0508813 A BRPI0508813 A BR PI0508813A
Authority
BR
Brazil
Prior art keywords
hib
vaccines
conjugate
low dose
combination vaccines
Prior art date
Application number
BRPI0508813-5A
Other languages
English (en)
Inventor
Mario Contorni
Original Assignee
Chiron Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32117706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0508813(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Srl filed Critical Chiron Srl
Publication of BRPI0508813A publication Critical patent/BRPI0508813A/pt
Publication of BRPI0508813B1 publication Critical patent/BRPI0508813B1/pt
Publication of BRPI0508813B8 publication Critical patent/BRPI0508813B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)

Abstract

VACINAS DE COMBINAçãO COM BAIXA DOSE DE CONJUGADO DE HIB Vacinas de combinação incluindo antígenos para imunizar contra difteria, tétano, coqueluche e Hib são conhecidas (vacinas "DTP-Hib" ). A invenção está direcionada à necessidade por tais vacina com baixas doses de antígeno de Hib, para reduzir custos, que não requerem reconstituição no campo. Assim, a invenção fornece uma vacina de combinação compreendendo antígenos para proteger um indivíduo contra pelo menos difteria, tétano, coqueluche e Hib, onde: (a) o antígeno para proteger contra Hib é um conjugado de um sacarídeo capsular de Hib; (b) a concentração do conjugado de Hib na vacina é < 15 <109>g/mL; e (c) o conjugado de Hib nunca foi liofilizado. Descobriu-se que as vacinas da invenção são seguras e altamente imunogênicas.
BRPI0508813A 2004-03-15 2005-03-14 vacinas líquidas de combinação com baixa dose de conjugado de hib BRPI0508813B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0405787.3 2004-03-15
GBGB0405787.3A GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines
PCT/IB2005/000927 WO2005089794A2 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate

Publications (3)

Publication Number Publication Date
BRPI0508813A true BRPI0508813A (pt) 2007-08-07
BRPI0508813B1 BRPI0508813B1 (pt) 2019-05-21
BRPI0508813B8 BRPI0508813B8 (pt) 2021-05-25

Family

ID=32117706

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508813A BRPI0508813B8 (pt) 2004-03-15 2005-03-14 vacinas líquidas de combinação com baixa dose de conjugado de hib

Country Status (13)

Country Link
US (2) US20090208526A1 (pt)
EP (1) EP1725258B1 (pt)
JP (2) JP4954056B2 (pt)
CN (2) CN1968711B (pt)
AT (1) ATE480257T1 (pt)
BR (1) BRPI0508813B8 (pt)
CA (1) CA2559996C (pt)
DE (1) DE602005023422D1 (pt)
DK (1) DK1725258T3 (pt)
GB (1) GB0405787D0 (pt)
RU (1) RU2435609C2 (pt)
SG (1) SG151253A1 (pt)
WO (1) WO2005089794A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241495B2 (en) 2005-06-27 2022-02-08 Glaxosmithkline Biologicals S.A. Immunogenic composition

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279748A1 (en) * 2000-06-29 2011-02-02 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
HRP20120557T1 (hr) 2006-09-07 2012-07-31 GlaxoSmithKline@Biologicals@s@a Kombinirano cjepivo sa smanjenim količinama antigena poliovirusa
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
RU2009149359A (ru) * 2007-06-04 2011-07-20 Новартис АГ (CH) Состав вакцин против менингита
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
CA2726824A1 (en) 2008-05-01 2009-11-05 Arecor Limited Protein formulation
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
CN102655879B (zh) * 2009-12-16 2016-03-09 印度血清研究所 疫苗组合物
EP2719395A1 (en) 2010-09-01 2014-04-16 Novartis AG Adsorption of immunopotentiators to insoluble metal salts
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
CN105148285B (zh) 2011-04-21 2019-02-12 塔夫茨大学信托人 用于活性试剂稳定化的方法和组合物
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
EP2911676B1 (en) * 2012-10-29 2020-05-20 The Board of Trustees of the University of Arkansas Novel mucosal adjuvants and delivery systems
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
KR102388325B1 (ko) * 2016-10-20 2022-04-18 케이엠 바이올로직스 가부시키가이샤 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법
CA3070039A1 (en) 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
CN110251667A (zh) * 2018-05-11 2019-09-20 武汉博沃生物科技有限公司 一种免疫组合制剂及其制备方法和应用
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN118903397A (zh) * 2024-10-12 2024-11-08 成都迈科康生物科技有限公司 GloboH六糖、linker化合物、蛋白偶联物及免疫原性组合物在治疗或抑制上皮性肿瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
AU696338B2 (en) * 1995-06-23 1998-09-10 Smithkline Beecham Biologicals (Sa) A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
EP2279748A1 (en) * 2000-06-29 2011-02-02 SmithKline Beecham Biologicals S.A. Multivalent vaccine composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241495B2 (en) 2005-06-27 2022-02-08 Glaxosmithkline Biologicals S.A. Immunogenic composition

Also Published As

Publication number Publication date
CA2559996A1 (en) 2005-09-29
CN1968711B (zh) 2011-01-05
JP2007529503A (ja) 2007-10-25
EP1725258A2 (en) 2006-11-29
CA2559996C (en) 2014-08-05
BRPI0508813B8 (pt) 2021-05-25
ATE480257T1 (de) 2010-09-15
DK1725258T3 (da) 2010-11-01
CN102028944B (zh) 2013-12-04
US20120107346A1 (en) 2012-05-03
RU2006136212A (ru) 2008-04-27
WO2005089794A3 (en) 2006-03-09
DE602005023422D1 (de) 2010-10-21
JP2008150397A (ja) 2008-07-03
US9259460B2 (en) 2016-02-16
CN1968711A (zh) 2007-05-23
JP4954056B2 (ja) 2012-06-13
BRPI0508813B1 (pt) 2019-05-21
EP1725258B1 (en) 2010-09-08
US20090208526A1 (en) 2009-08-20
CN102028944A (zh) 2011-04-27
SG151253A1 (en) 2009-04-30
RU2435609C2 (ru) 2011-12-10
WO2005089794A2 (en) 2005-09-29
GB0405787D0 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
BRPI0508813A (pt) vacinas de combinação com baixa dose de conjugado de hib
Reed et al. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
ES2164251T5 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
ES2388690T3 (es) Composición de vacuna multivalente
CN111212846B (zh) 三萜皂苷类似物
UY26801A1 (es) Composición de vacuna
MA29601B1 (fr) Vaccin antipaludeen
BR0310062A (pt) Vacinas mucosas com adjuvante de quitosana e/ou antìgenos meningocócicos
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
MA30065B1 (fr) Vaccin
CY1115308T1 (el) Συνθεσεις εμβολιου οι οποιες περιεχουν ανοσοενισχυτικο εκδοχο σαπωνινης
HU229968B1 (hu) Sztreptokokkusz oltóanyag
ATE350057T1 (de) Impfstoffzusammesetzung
MY169275A (en) Method of immunization against the four serotypes of dengue
DK1835939T3 (da) Meningokokkonjugatvaccination
JP2015531389A5 (pt)
BRPI0510315A (pt) integração de vacinação com conjugado meningocócico
RU2015106745A (ru) Иммуногенные композиции
Sun et al. Adjuvant effect of water-soluble polysaccharide (PAP) from the mycelium of Polyporus albicans on the immune responses to ovalbumin in mice
BRPI0606165A2 (pt) método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
BR0208980A (pt) Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses
BR112022002094A2 (pt) Composição imunogênica
Akter et al. Glycoconjugate Vaccine: An Effective Way to Combat Infectious Diseases and Cancers

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L. (IT)

B25D Requested change of name of applicant approved

Owner name: GSK VACCINES S.R.L. (IT)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.